QIAGEN N.V. Q1 2026 Results and Updated Full-Year Outlook

QIAGEN N.V. reported preliminary Q1 2026 results, with adjusted diluted EPS meeting expectations but sales trends being mixed. While sample technologies, QIAcuity, and QIAGEN Digital Insights showed solid growth, QuantiFERON sales declined by 5% CER due to decreased demand for immigration testing in the US and Middle East. Consequently, QIAGEN has revised its full-year 2026 outlook. Net sales growth is now expected to be around 1-2% CER (down from at least 5% CER), and adjusted diluted EPS are projected to be at least $2.43 CER (down from at least $2.50 CER). The company anticipates stronger growth in the second half of 2026, driven by product launches, an anticipated recovery in QuantiFERON sales, and contributions from the Parse acquisition. For Q2 2026, net sales are expected to decline approximately 2% CER, with adjusted diluted EPS remaining stable at $0.60 CER.